Infosys Q4 Results: Attrition rate declines further to 12.6%
Thu, Apr 18, 2024 5:36 PM

Infosys Q4 Results: Attrition rate declines further to 12.6%

A Flip by Avya Verma
Get it on Google Play
Infosys reported lower-than-expected fourth-quarter revenue on Thursday to clock a net profit of ₹7,975 crore. The company also saw attrition dwindle further to 12.6% in the final quarter of FY24.Attrition rates have steadily declined over the past year — from 20.90% in Q4FY23 to 12.6% in the results shared on Thursday. It stood at 17.30% in the first quarter of FY24 before dipping to 14.6%.

More great flips

Weekly Stock picks: ICICI Direct suggests these two shares to buy or sell

Weekly Stock picks: ICICI Direct suggests these two shares to buy or sell

Indian stock market: The Indian stock market indices, Sensex and the Nifty 50, ended Tuesday, April 30, trading session in negative, attributed to a late-session selloff influenced by weak global cues. The stock market remained closed on Wednesday, May 1 on account of Maharashtra Day.On Tuesday, Sensex concluded the session 189 points lower, representing a decrease of 0.25 percent.

Open Flip
S&P, Nasdaq open lower as investors take cover before Fed decision

S&P, Nasdaq open lower as investors take cover before Fed decision

The S&P 500 and Nasdaq opened lower on Wednesday as chip stocks led losses after downbeat results and markets exercised caution ahead of more economic data and the Federal Reserve's interest rate decision later in the day. The Dow Jones Industrial Average rose 29.6 points, or 0.08%, at the open to 37,845.56. The S&P 500 fell 6.7 points, or 0.13%, at the open to 5,029.03.

Open Flip
Johnson & Johnson seeks backing for $11 billion baby powder cancer drug

Johnson & Johnson seeks backing for $11 billion baby powder cancer drug

Johnson & Johnson will ask thousands of people suing over its allegedly tainted baby powder to vote for a settlement that would resolve all litigation for $11 billion — $2.1 billion more than the company offered last year.In a news release Wednesday, J&J urged those who blame the talc-based powder for ovarian cancer to support a third bankruptcy.

Open Flip

Join our Smart Investment Community

More than 1 Million users are using FlipItMoney to stay updated about the business and finance world! Join FlipItMoney now and take smart investment decisions!
Icon